Cargando…
Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
SIMPLE SUMMARY: Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. A better understanding of the biology and molecular basis of disease progression has resulted in several drug targets being identified and led to approval of several new drugs for...
Autores principales: | Kohli, Manish, Tan, Winston, Vire, Bérengère, Liaud, Pierre, Blairvacq, Mélina, Berthier, Frederic, Rouison, Daniel, Garnier, George, Payen, Léa, Cousin, Thierry, Joubert, Dominique, Prieur, Alexandre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864155/ https://www.ncbi.nlm.nih.gov/pubmed/33498444 http://dx.doi.org/10.3390/cancers13030375 |
Ejemplares similares
-
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019) -
Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
por: Prieur, Alexandre, et al.
Publicado: (2023) -
hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022) -
hPG(80) (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study
por: Casile, Melanie, et al.
Publicado: (2023) -
Association between post-operative hPG(80) (circulating progastrin) detectable level and worse prognosis in glioblastoma
por: Doucet, L., et al.
Publicado: (2023)